SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-012870
Filing Date
2023-04-14
Accepted
2023-04-14 16:01:18
Documents
13
Period of Report
2023-04-13
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trvi-20230413.htm   iXBRL 8-K 72664
2 EX-3.1 trvi-ex3_1.htm EX-3 225680
  Complete submission text file 0000950170-23-012870.txt   451742

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT trvi-20230413_pre.xml EX-101.PRE 11896
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trvi-20230413.xsd EX-101.SCH 2497
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT trvi-20230413_lab.xml EX-101.LAB 14809
7 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20230413_htm.xml XML 5069
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 23821075
SIC: 2834 Pharmaceutical Preparations